KR101534422B1 - 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 - Google Patents

귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 Download PDF

Info

Publication number
KR101534422B1
KR101534422B1 KR1020137021389A KR20137021389A KR101534422B1 KR 101534422 B1 KR101534422 B1 KR 101534422B1 KR 1020137021389 A KR1020137021389 A KR 1020137021389A KR 20137021389 A KR20137021389 A KR 20137021389A KR 101534422 B1 KR101534422 B1 KR 101534422B1
Authority
KR
South Korea
Prior art keywords
ear
disclosed
corticosteroid
formulations
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020137021389A
Other languages
English (en)
Korean (ko)
Other versions
KR20130100017A (ko
Inventor
제이 리히터
베네딕트 폴라스
앤드류 엠 트래멀
세르지오 지 듀론
파브리스 피우
루이스 에이 델러머리
퀴앙 이
칼 르벨
마이클 크리스토퍼 스카이프
제프리 피 해리스
Original Assignee
오토노미, 인코포레이티드
더 리젠츠 오브 더 유니버시티 오브 캘리포니아
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41319223&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101534422(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0823378A external-priority patent/GB2459910B/en
Application filed by 오토노미, 인코포레이티드, 더 리젠츠 오브 더 유니버시티 오브 캘리포니아 filed Critical 오토노미, 인코포레이티드
Publication of KR20130100017A publication Critical patent/KR20130100017A/ko
Application granted granted Critical
Publication of KR101534422B1 publication Critical patent/KR101534422B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0046—Ear
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020137021389A 2008-05-14 2009-05-14 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법 Expired - Fee Related KR101534422B1 (ko)

Applications Claiming Priority (21)

Application Number Priority Date Filing Date Title
US12771308P 2008-05-14 2008-05-14
US61/127,713 2008-05-14
US6042508P 2008-06-10 2008-06-10
US61/060,425 2008-06-10
US7458308P 2008-06-20 2008-06-20
US61/074,583 2008-06-20
US8245008P 2008-07-21 2008-07-21
US61/082,450 2008-07-21
US8794008P 2008-08-11 2008-08-11
US61/087,940 2008-08-11
US9438408P 2008-09-04 2008-09-04
US61/094,384 2008-09-04
US9524808P 2008-09-08 2008-09-08
US61/095,248 2008-09-08
US10111208P 2008-09-29 2008-09-29
US61/101,112 2008-09-29
US14003308P 2008-12-22 2008-12-22
GB0823378A GB2459910B (en) 2008-04-21 2008-12-22 Controlled Release Corticosteroid Compositions and Methods for the Treatment of Otic Disorders
US61/140,033 2008-12-22
GB0823378.5 2008-12-22
PCT/US2009/003066 WO2009139924A2 (en) 2008-05-14 2009-05-14 Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020107026567A Division KR101477329B1 (ko) 2008-05-14 2009-05-14 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법

Publications (2)

Publication Number Publication Date
KR20130100017A KR20130100017A (ko) 2013-09-06
KR101534422B1 true KR101534422B1 (ko) 2015-07-09

Family

ID=41319223

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020137021389A Expired - Fee Related KR101534422B1 (ko) 2008-05-14 2009-05-14 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
KR1020107026567A Expired - Fee Related KR101477329B1 (ko) 2008-05-14 2009-05-14 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020107026567A Expired - Fee Related KR101477329B1 (ko) 2008-05-14 2009-05-14 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법

Country Status (14)

Country Link
US (9) US8030297B2 (enExample)
EP (1) EP2303227B1 (enExample)
JP (3) JP5551685B2 (enExample)
KR (2) KR101534422B1 (enExample)
CN (2) CN102026623B (enExample)
AU (1) AU2009246870B2 (enExample)
BR (1) BRPI0912482A2 (enExample)
CA (1) CA2723458C (enExample)
IL (2) IL208806A (enExample)
MX (1) MX2010012397A (enExample)
MY (1) MY161021A (enExample)
RU (2) RU2469726C2 (enExample)
WO (1) WO2009139924A2 (enExample)
ZA (1) ZA201007482B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019066505A1 (ko) * 2017-09-29 2019-04-04 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130079749A1 (en) * 2007-08-29 2013-03-28 Advanced Bionics, Llc Modular Drug Delivery System for Minimizing Trauma During and After Insertion of a Cochlear Lead
AU2009219426B2 (en) * 2008-02-25 2015-12-03 Eyegate Pharmaceuticals, Inc. Enhanced delivery of a therapeutic to ocular tissues through iontophoresis
KR20210107137A (ko) 2008-04-21 2021-08-31 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
US11969501B2 (en) 2008-04-21 2024-04-30 Dompé Farmaceutici S.P.A. Auris formulations for treating otic diseases and conditions
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
US8648119B2 (en) * 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
EP2296632A4 (en) * 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
US8784870B2 (en) * 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US20100016450A1 (en) * 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
CA2731769C (en) * 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) * 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
CA2751761A1 (en) 2008-10-22 2010-04-29 House Ear Institute Treatment and/or prevention of inner ear conditions by modulation of a metabotropic glutamate receptor
JP6013736B2 (ja) * 2008-12-22 2016-10-25 オトノミ—，インク． 耳の障害の処置のための耳感覚細胞モジュレータ組成物の制御放出及びその方法
US20140076336A1 (en) * 2009-09-17 2014-03-20 Ascentia Health, Inc. Ear insert for relief of tmj discomfort and headaches
MX359879B (es) * 2009-10-02 2018-10-12 Foamix Pharmaceuticals Ltd Composiciones tópicas de tetraciclina.
WO2011049958A2 (en) * 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
JP6012112B2 (ja) * 2011-02-18 2016-10-25 オトノミ—，インク． 薬物により誘発される耳毒性の予防又は回復
EP2734557B1 (en) * 2011-07-20 2022-09-07 UroGen Pharma Ltd. Production of thermoreversible hydrogels for therapeutic applications
AU2012331702B2 (en) 2011-11-04 2017-10-26 Laurentia Holding B.V. Liposomal corticosteroids for treatment of inflammatory disorders in humans
CA2862406C (en) 2012-01-10 2024-06-18 Entrx LLC Otic formulations, methods and devices
HK1211875A1 (en) 2012-09-07 2016-06-03 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014056097A1 (en) 2012-10-12 2014-04-17 Litens Automotive Partnership Isolator for use with engine that is assisted or started by an mgu or a motor through an endless drive member
US9849126B2 (en) 2013-01-03 2017-12-26 Entrx LLC Sterile otic formulations
CA2897467C (en) 2013-01-23 2020-09-22 Semnur Pharmaceuticals, Inc. Pharmaceutical formulation comprising an insoluble corticosteroid and a soluble corticosteroid
WO2014134184A1 (en) * 2013-02-28 2014-09-04 Anida Pharma Inc. Methods of treating ototoxicity
CA2946832A1 (en) * 2013-04-25 2014-10-30 Seachaid Pharmaceuticals, Inc. Oral cefepime compositions and uses thereof
US9931068B2 (en) 2013-08-21 2018-04-03 Senseonics, Incorporated Drug elution for in vivo protection of bio-sensing analytes
AU2014311358A1 (en) 2013-08-27 2016-04-07 Otonomy, Inc. Treatment of pediatric otic disorders
CN103751779A (zh) * 2014-02-25 2014-04-30 中国农业科学院上海兽医研究所 O型口蹄疫多肽的泊洛沙姆凝胶佐剂
CN104644545A (zh) * 2015-02-27 2015-05-27 苏州丝美特生物技术有限公司 一种治疗内耳疾病的控释缓释丝素蛋白凝胶制剂
KR101628707B1 (ko) * 2014-05-29 2016-06-10 한남대학교 산학협력단 난청 치료용 약물 전달 시스템 및 이의 제조방법
EP3174525A4 (en) * 2014-07-29 2018-05-02 Otonomy, Inc. Otic formulations for the treatment of ceruminosis
FR3024361B1 (fr) * 2014-07-30 2017-11-24 Affichem Utilisation de derives de sterols pour traitement de la perte auditive neurosensorielle et composition correspondante
TWI674899B (zh) 2015-01-21 2019-10-21 美商桑紐爾製藥公司 醫藥配方
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
US9375478B1 (en) 2015-01-30 2016-06-28 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9937223B2 (en) 2015-01-30 2018-04-10 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9750785B2 (en) 2015-01-30 2017-09-05 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9925233B2 (en) 2015-01-30 2018-03-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9687526B2 (en) 2015-01-30 2017-06-27 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
US9744209B2 (en) 2015-01-30 2017-08-29 Par Pharmaceutical, Inc. Vasopressin formulations for use in treatment of hypotension
TWI773641B (zh) 2015-05-08 2022-08-11 日商活效製藥股份有限公司 含有糖皮質類固醇（ｇｌｕｃｏｃｏｒｔｉｃｏｉｄｓ）之奈米微粒子之水性懸浮液劑
EP3328898B8 (en) * 2015-07-28 2024-04-10 6452728 Canada Corp. Trkb or trkc agonist compositions and methods for the treatment of otic conditions
US11185536B2 (en) 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
US20170196802A1 (en) * 2016-01-08 2017-07-13 Abon Pharmaceuticals, Llc Long Acting Injectable Formulations
WO2018193423A1 (en) * 2017-04-21 2018-10-25 Ferring B.V. Oral pharmaceutical compositions of corticosteroids
EP3641728B9 (en) * 2017-06-23 2021-06-30 Laboratorios SALVAT, S.A. An oil-in-water nanoemulsion composition of clobetasol
KR20190038368A (ko) * 2017-09-29 2019-04-08 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법
CN107823636A (zh) * 2017-12-14 2018-03-23 阜阳市平衡医疗保健器械有限公司 一种治疗耳鸣的药物
CN108403628B (zh) * 2018-05-21 2021-01-08 北京和舆医药科技有限公司 一种地塞米松磷酸钠注射剂
AU2019365253B2 (en) * 2018-10-24 2025-02-20 Ferring B.V. Mucoadhesive pharmaceutical compositions of corticosteroids
US11672860B2 (en) 2018-11-02 2023-06-13 Senseonics, Incorporated Drug eluting matrix on analyte indicator
WO2020132514A1 (en) 2018-12-21 2020-06-25 Qmark Medical Inc. Hydrogel composition for mucosal lifting procedures within lumenal anatomical structures
US20200214976A1 (en) * 2019-01-09 2020-07-09 Spiral Therapeutics, Inc. Self-gelling solutions for administration of therapeutics to the inner ear
US10561736B1 (en) 2019-01-09 2020-02-18 Spiral Therapeutics, Inc. Apoptosis inhibitor formulations for prevention of hearing loss
KR20210131341A (ko) * 2019-02-27 2021-11-02 오티카라 인코포레이티드 비, 부비, 및 비인두 조직 감염 및/또는 염증의 치료 방법
US12390510B2 (en) 2019-05-29 2025-08-19 Massachusetts Eye And Ear Infirmary Methods of treating sensorineural hearing loss using fibroblast growth factor 2 (FGF2)
KR102425971B1 (ko) * 2020-06-02 2022-07-28 충남대학교산학협력단 덱사메타손 및 소듐 카프르산을 포함하는 내이 전달용 조성물
CA3188400A1 (en) * 2020-08-03 2022-02-10 Daniel S. Kohane Thermo-sensitive permeation enhancing formulations for drug delivery
US20230364188A1 (en) * 2020-09-25 2023-11-16 Astellas Pharma Inc. Pharmaceutical composition for otic administration
EP4279061A1 (en) * 2022-05-18 2023-11-22 Acousia Therapeutics GmbH Aqueous gel composition
KR20240086291A (ko) * 2022-12-09 2024-06-18 가톨릭대학교 산학협력단 약물　전달용 조성물 및 이의 용도
WO2025072841A1 (en) * 2023-09-28 2025-04-03 Syntis Bio, Inc. Synergistic permeation enhancers for gastrointestinal synthetic epithelial linings

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers

Family Cites Families (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4188373A (en) * 1976-02-26 1980-02-12 Cooper Laboratories, Inc. Clear, water-miscible, liquid pharmaceutical vehicles and compositions which gel at body temperature for drug delivery to mucous membranes
US4478822A (en) 1983-05-16 1984-10-23 Merck & Co., Inc. Drug delivery system utilizing thermosetting gels
US4968507A (en) * 1984-06-20 1990-11-06 Merck & Co., Inc. Controlled porosity osmotic pump
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5702716A (en) 1988-10-03 1997-12-30 Atrix Laboratories, Inc. Polymeric compositions useful as controlled release implants
US4938763B1 (en) 1988-10-03 1995-07-04 Atrix Lab Inc Biodegradable in-situ forming implants and method of producing the same
US5324519A (en) 1989-07-24 1994-06-28 Atrix Laboratories, Inc. Biodegradable polymer composition
IT1251151B (it) 1991-08-05 1995-05-04 Fidia Spa Materiale spugnoso essenzialmente costituito da acido ialuronico,o suoi derivati
EP0551626A1 (en) * 1991-12-19 1993-07-21 LEK, tovarna farmacevtskih in kemicnih izdelkov, d.d. Thermoreversible gel as a liquid pharmaceutical carrier for a galenic formulation
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
CA2153234C (en) * 1993-04-16 1999-02-16 Masanobu Takeuchi Aqueous drug composition having property of reversible thermosetting gelation
US5421818A (en) 1993-10-18 1995-06-06 Inner Ear Medical Delivery Systems, Inc. Multi-functional inner ear treatment and diagnostic system
AU1119895A (en) 1993-11-30 1995-06-19 Zenichi Ogita External preparation
JP3696265B2 (ja) 1994-02-04 2005-09-14 日本オルガノン株式会社 点鼻液剤
DK1125577T3 (da) 1994-04-08 2006-06-19 Qlt Usa Inc Væskeformige medikamentindföringspræparater
US6201065B1 (en) 1995-07-28 2001-03-13 Focal, Inc. Multiblock biodegradable hydrogels for drug delivery and tissue treatment
FR2742357B1 (fr) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa Nanoparticules stabilisees et filtrables dans des conditions steriles
AU2676397A (en) 1996-04-18 1997-11-07 University Technology Corporation Methods for treating middle and inner ear disorders
US5861174A (en) 1996-07-12 1999-01-19 University Technology Corporation Temperature sensitive gel for sustained delivery of protein drugs
NL1004214C2 (nl) * 1996-10-07 1998-04-10 Avebe Coop Verkoop Prod Toepassing van gemodificeerd zetmeel als middel voor het vormen van een thermoreversibele gel.
US6004573A (en) 1997-10-03 1999-12-21 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6117949A (en) 1998-10-01 2000-09-12 Macromed, Inc. Biodegradable low molecular weight triblock poly (lactide-co-glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6201072B1 (en) 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
IL135774A0 (en) 1997-10-22 2001-05-20 Ponikau Jens Use of antinfungal agents for the topical treatment of fungus-induced mucositis
DE19748763A1 (de) 1997-11-05 1999-05-06 Hans Peter Zenner Verwendung von Vasopressin-Antagonisten
SE9704186D0 (sv) 1997-11-14 1997-11-14 Astra Ab New composition of matter
US6649621B2 (en) 1997-12-16 2003-11-18 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
US6177434B1 (en) 1997-12-16 2001-01-23 The United States Of America As Represented By The Secretary Of The Navy Prevention or reversal of sensorineural hearing loss (SNHL) through biologic mechanisms
CA2316248A1 (en) 1997-12-23 1999-07-01 Alliance Pharmaceutical Corp. Methods and compositions for the delivery of pharmaceutical agents and/or the prevention of adhesions
US6316011B1 (en) 1998-08-04 2001-11-13 Madash, Llc End modified thermal responsive hydrogels
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6740664B2 (en) 1998-09-30 2004-05-25 Alcon, Inc. Methods for treating otic and ophthalmic infections
WO2000050005A1 (en) 1999-02-24 2000-08-31 Dong Wha Pharm. Ind. Co., Ltd Liquid suppository composition of diclofenac sodium
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6287588B1 (en) 1999-04-29 2001-09-11 Macromed, Inc. Agent delivering system comprised of microparticle and biodegradable gel with an improved releasing profile and methods of use thereof
JP2003510263A (ja) 1999-09-24 2003-03-18 アルコン，インコーポレイテッド シプロフロキサシンおよびデキサメタゾンを含有する局所用懸濁処方物
US20040082509A1 (en) 1999-10-12 2004-04-29 Christophe Bonny Cell-permeable peptide inhibitors of the JNK signal transduction pathway
MXPA02008966A (es) 2000-03-14 2003-02-12 Alcon Inc Viscoelasticos para uso en cirugia del oido medio.
US6548527B2 (en) * 2000-03-27 2003-04-15 The General Hospital Corporation Treatments for immune-mediated ear disorders
US6998137B2 (en) 2000-04-07 2006-02-14 Macromed, Inc. Proteins deposited onto sparingly soluble biocompatible particles for controlled protein release into a biological environment from a polymer matrix
US7758888B2 (en) 2000-04-21 2010-07-20 Sol-Gel Technologies Ltd. Composition exhibiting enhanced formulation stability and delivery of topical active ingredients
US6589549B2 (en) 2000-04-27 2003-07-08 Macromed, Incorporated Bioactive agent delivering system comprised of microparticles within a biodegradable to improve release profiles
DE10346940B3 (de) 2003-10-06 2005-06-16 Schering Ag Substituierte Pentanole, ihre Verwendung zur Herstellung von Arzneimitteln speziell Entzündungshemmer sowie diese enthaltende pharmazeutische Präparate
PE20020578A1 (es) 2000-10-10 2002-08-14 Upjohn Co Una composicion de antibiotico topico para el tratamiento de infecciones oculares
SE0100158D0 (sv) 2001-01-19 2001-01-19 Synphora Ab Novel method and composition for local treatment of Meniere´s disease and tinnitus
US20060269602A1 (en) 2001-04-13 2006-11-30 Dasch James R Method of modifying the release profile of sustained release compositions
TWI324925B (en) * 2001-08-23 2010-05-21 Novartis Ag Ophthalmic composition
US6488952B1 (en) 2001-08-28 2002-12-03 John P. Kennedy Semisolid therapeutic delivery system and combination semisolid, multiparticulate, therapeutic delivery system
EP1429780B1 (en) 2001-09-21 2005-12-21 Alcon, Inc. Method of treating middle ear infections
US7001615B1 (en) 2001-12-07 2006-02-21 Alcon, Inc. Sustained release ophthalmic, otic and nasal suspension
DE10162593A1 (de) 2001-12-19 2003-07-03 Menarini Ricerche Spa Stabilisierte topische Brivudin-Formulierungen
US20030229333A1 (en) 2002-02-22 2003-12-11 Control Delivery Systems, Inc. Methods for treating otic disorders
US20060013858A1 (en) 2002-10-29 2006-01-19 Trune Dennis R Fludrocortisone treatment for hearing loss
US20040101506A1 (en) 2002-11-25 2004-05-27 Fust Charles A. Composition for the prevention and treatment of inflammation of the ear
US7220431B2 (en) 2002-11-27 2007-05-22 Regents Of The University Of Minnesota Methods and compositions for applying pharmacologic agents to the ear
WO2004093870A1 (en) 2003-03-20 2004-11-04 Pharmacia Corporation Treatment and prevention of otic disorders
WO2005046438A2 (en) 2003-11-06 2005-05-26 Pluromed, Inc. Internal clamp for surgical procedures
US20050191270A1 (en) * 2004-02-27 2005-09-01 Hydromer, Inc. Anti-infectious hydrogel compositions
US20060063802A1 (en) 2004-03-29 2006-03-23 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8268866B2 (en) 2004-03-29 2012-09-18 Matthieu Guitton Methods for the treatment of tinnitus induced by cochlear excitotoxicity
US8870826B2 (en) 2004-05-24 2014-10-28 Auris Medical Llc Combined otic aspirator and medication dispenser
US7858115B2 (en) 2004-06-24 2010-12-28 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
US20060046970A1 (en) * 2004-08-31 2006-03-02 Insite Vision Incorporated Topical otic compositions and methods of topical treatment of prevention of otic infections
AU2005282571A1 (en) 2004-09-03 2006-03-16 Piedmont Pharmaceuticals, Llc Methods for transmembrane treatment and prevention of otitis media
JP2006111585A (ja) 2004-10-15 2006-04-27 Mebiol Kk 徐放性組成物およびその徐放方法
JP2008537684A (ja) 2005-01-24 2008-09-25 ニューロシステック コーポレイション 内耳およびその他の組織へ治療薬および／またはその他の薬剤を送達するための装置および方法
WO2006099325A2 (en) 2005-03-10 2006-09-21 3M Innovative Properties Company Methods of treating ear infections
CA2601179A1 (en) * 2005-03-16 2006-09-21 Elan Pharma International Limited Nanoparticulate leukotriene receptor antagonist/corticosteroid formulations
EP1863453A2 (en) * 2005-03-29 2007-12-12 Evonik Röhm GmbH Multiparticulate pharmaceutical form comprising pellets with a substance having a modular effect in relation to active ingredient release
US20060257488A1 (en) 2005-05-10 2006-11-16 Cytophil, Inc. Injectable hydrogels and methods of making and using same
KR101041843B1 (ko) 2005-07-30 2011-06-17 삼성엘이디 주식회사 질화물계 화합물 반도체 발광소자 및 그 제조방법
WO2007025142A2 (en) 2005-08-26 2007-03-01 Ladd Byron S Gel compositions comprising a combination of an antiseptic and an anesthetic agent for treating surface areas in medical and surgical procedures
WO2007031098A1 (en) 2005-09-12 2007-03-22 Xigen S.A. Cell-permeable peptide inhibitors of the jnk signal transduction pathway
CA2622002A1 (en) 2005-09-26 2007-04-05 Piedmont Pharmaceuticals Llc Methods for treatment and prevention of otitis media using nonionic surfactants to facilitate transmembrane drug delivery into the middle ear
JP2009509955A (ja) 2005-09-26 2009-03-12 ピードモント ファーマシューティカルズ リミテッド ライアビリティ カンパニー 化学的浸透促進剤を使用して中耳内への経膜的薬物送達を促進する、中耳炎の処置および予防のための方法
KR101271263B1 (ko) * 2005-09-28 2013-06-07 아우리스 메디칼 아게 내이 장애 치료용 약학 조성물
US20070110788A1 (en) 2005-11-14 2007-05-17 Hissong James B Injectable formulation capable of forming a drug-releasing device
FR2894585B1 (fr) 2005-12-14 2012-04-27 Rhodia Recherches Et Tech Copolymere comprenant des unites zwitterioniques et d'autres unites, composition comprenant le copolymere, et utilisation
US20070178051A1 (en) * 2006-01-27 2007-08-02 Elan Pharma International, Ltd. Sterilized nanoparticulate glucocorticosteroid formulations
CA2655596C (en) 2006-06-27 2011-10-25 Biovail Laboratories International Srl Multiparticulate osmotic delivery system
US20080103118A1 (en) 2006-10-27 2008-05-01 Iomedix Development International Srl Composition for improving blood cholesterol levels
JP2010509919A (ja) 2006-11-15 2010-04-02 マサチューセッツ・アイ・アンド・イア・インファーマリー 内耳細胞の生成
JP2010512230A (ja) 2006-12-11 2010-04-22 プルーロームド インコーポレイテッド 灌流臓器止血法
US20100197800A1 (en) 2007-04-23 2010-08-05 Richard Friedman Treatment and/or Prevention of Presbycusis by Modulation of Metabotropic Glutamate Receptor 7
US7795231B2 (en) 2007-10-04 2010-09-14 Insite Vision Incorporated Concentrated aqueous azalide formulations
KR20210107137A (ko) 2008-04-21 2021-08-31 오토노미, 인코포레이티드 귀 질환 및 병태를 치료하기 위한 귀 조제물
CN102026623B (zh) 2008-05-14 2013-08-14 奥德纳米有限公司 用于治疗耳部病症的控制释放皮质类固醇组合物和方法
WO2009142719A2 (en) 2008-05-19 2009-11-26 Massachusetts Institute Of Technology Tympanic membrane permeating ear drops and uses thereof
US8648119B2 (en) 2008-05-23 2014-02-11 Otonomy, Inc. Controlled release immunomodulator compositions and methods for the treatment of otic disorders
US8846770B2 (en) 2008-06-18 2014-09-30 Otonomy, Inc. Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders
US8349353B2 (en) 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders
WO2010011466A2 (en) 2008-06-27 2010-01-28 Otonomy, Inc. Controlled-release cns modulating compositions and methods for the treatment of otic disorders
EP2296632A4 (en) 2008-07-14 2014-11-12 Otonomy Inc COMPOSITIONS AND METHODS FOR MODULATING CONTROLLED RELEASE APOPTOSIS FOR THE TREATMENT OF OTIC DISORDERS
CA2731769C (en) 2008-07-21 2013-09-10 Otonomy, Inc. Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
US8399018B2 (en) 2008-07-21 2013-03-19 Otonomy, Inc. Controlled release ion channel modulator compositions and methods for the treatment of otic disorders
US20100016450A1 (en) 2008-07-21 2010-01-21 Otonomy, Inc. Controlled release delivery devices for the treatment of otic disorders
US8318817B2 (en) 2008-07-21 2012-11-27 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8784870B2 (en) 2008-07-21 2014-07-22 Otonomy, Inc. Controlled release compositions for modulating free-radical induced damage and methods of use thereof
EP2299979B1 (en) 2008-07-21 2020-11-25 Otonomy, Inc. Controlled release antimicrobial compositions and methods for the treatment of otic disorders
US8496957B2 (en) 2008-07-21 2013-07-30 Otonomy, Inc Controlled release auris sensory cell modulator compositions and methods for the treatment of otic disorders
CN101664381A (zh) 2009-08-21 2010-03-10 天津生机集团股份有限公司 治疗奶牛乳房炎的原位凝胶缓释制剂的制备方法
WO2011049958A2 (en) 2009-10-21 2011-04-28 Otonomy, Inc. Modulation of gel temperature of poloxamer-containing formulations
ES2369101B2 (es) 2010-05-07 2012-08-02 Universidade De Santiago De Compostela Sistema farmacéutico acuoso para la administración de fármacos en las uñas.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5292516A (en) * 1990-05-01 1994-03-08 Mediventures, Inc. Body cavity drug delivery with thermoreversible gels containing polyoxyalkylene copolymers

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Hearing Research, 212(1-2), 236-244쪽(2006.02.) *
Hearing Research, 212(1-2), 236-244쪽(2006.02.)*
Otology & Neurotology, 22(4), 475-479쪽(2001.07.) *
Otology & Neurotology, 22(4), 475-479쪽(2001.07.)*

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019066505A1 (ko) * 2017-09-29 2019-04-04 주식회사 엘지화학 히알루론산 기반 하이드로겔 약제학적 안정화 조성물 및 그 제조방법

Also Published As

Publication number Publication date
US20110319375A1 (en) 2011-12-29
US20100009952A1 (en) 2010-01-14
US8030297B2 (en) 2011-10-04
US8546363B2 (en) 2013-10-01
CN102026623A (zh) 2011-04-20
WO2009139924A3 (en) 2010-04-01
US8680083B2 (en) 2014-03-25
JP5551685B2 (ja) 2014-07-16
IL208806A0 (en) 2011-01-31
ZA201007482B (en) 2012-01-25
IL244103A0 (en) 2016-04-21
RU2012139802A (ru) 2014-03-27
JP2014101392A (ja) 2014-06-05
US20110008456A1 (en) 2011-01-13
US8658626B2 (en) 2014-02-25
WO2009139924A2 (en) 2009-11-19
EP2303227A2 (en) 2011-04-06
US20110319373A1 (en) 2011-12-29
CN102026623B (zh) 2013-08-14
US20140364403A1 (en) 2014-12-11
US9744126B2 (en) 2017-08-29
CA2723458A1 (en) 2009-11-19
KR101477329B1 (ko) 2014-12-29
RU2469726C2 (ru) 2012-12-20
JP6014069B2 (ja) 2016-10-25
BRPI0912482A2 (pt) 2020-08-18
CA2723458C (en) 2014-01-28
CN103417472B (zh) 2018-01-02
JP2011529854A (ja) 2011-12-15
EP2303227A4 (en) 2012-10-31
US8828980B2 (en) 2014-09-09
US20150313838A1 (en) 2015-11-05
MY161021A (en) 2017-03-31
RU2010150863A (ru) 2012-06-20
JP2016153423A (ja) 2016-08-25
CN103417472A (zh) 2013-12-04
US20180110727A1 (en) 2018-04-26
US8680082B2 (en) 2014-03-25
KR20130100017A (ko) 2013-09-06
US20110319377A1 (en) 2011-12-29
US20110319374A1 (en) 2011-12-29
IL208806A (en) 2016-02-29
EP2303227B1 (en) 2021-10-06
MX2010012397A (es) 2011-03-15
HK1156533A1 (en) 2012-06-15
KR20100135321A (ko) 2010-12-24
AU2009246870B2 (en) 2013-08-01
US9511020B2 (en) 2016-12-06
AU2009246870A1 (en) 2009-11-19

Similar Documents

Publication Publication Date Title
KR101534422B1 (ko) 귀 질환 치료를 위한 제어 방출형 코르티코스테로이드 조성물 및 방법
KR101367479B1 (ko) 귀 질병 치료를 위한 제어 방출형 항미생물성 조성물 및 방법
JP2021510685A (ja) 成長因子耳用製剤
GB2459910A (en) Sustained release corticosteroid compositions for treatment of otic disorders
TWI382839B (zh) 控制釋放之皮質類固醇組成物及其用於耳部失調治療的方法
HK1191867B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
HK1191867A (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders
HK1156533B (en) Controlled release corticosteroid compositions and methods for the treatment of otic disorders

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

St.27 status event code: A-0-1-A10-A18-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

Fee payment year number: 1

St.27 status event code: A-2-2-U10-U12-oth-PR1002

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

Fee payment year number: 4

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 5

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PR1001 Payment of annual fee

Fee payment year number: 6

St.27 status event code: A-4-4-U10-U11-oth-PR1001

PC1903 Unpaid annual fee

Not in force date: 20210701

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

St.27 status event code: A-4-4-U10-U13-oth-PC1903

PC1903 Unpaid annual fee

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20210701

St.27 status event code: N-4-6-H10-H13-oth-PC1903